C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients

Sponsor

AstraZeneca (Industry)

Overall Status

Completed

CT.gov ID

NCT00688454

Collaborator

(none)

3,392

Enrollment

Duration (Months)

Study Details

Study Description

Brief Summary

The study explores efficacy and safety of the lipid-lowering therapy with CRESTOR in statin-naive patients and in patients with previously unsuccessful statin therapy. This study was designed to investigate the dynamic of the lipid parameters and therapy tolerability during 8-10 weeks treatment with CRESTOR

Condition or Disease	Intervention/Treatment	Phase
Hypercholesteremia

Study Design

Study Type:

Observational

Actual Enrollment :

3392 participants

Time Perspective:

Prospective

Official Title:

C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients

Study Start Date :

Feb 1, 2007

Actual Study Completion Date :

Jan 1, 2008

Arms and Interventions

Arm	Intervention/Treatment
Pt with hypercholesteremia Patients treated with CRESTOR because of hypercholesteremia

Outcome Measures

Primary Outcome Measures

LDL-Cholesterin, HDL-Cholesterin, Triglycerides, Total Cholesterin [3 visits within 10 weeks]

Secondary Outcome Measures

Tolerability of CRESTOR-therapy [3 visits within 10 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with hypercholesteremia who was never treated with statins before
Patient with hypercholesteremia who was treated with a statin (other then rosuvastatin) but because of its adverse effects/insufficient action was switched to therapy with CRESTOR